Exploring Genetic Associations in Systemic Lupus Erythematosus Through Mendelian Randomization: Implications for Novel Biomarkers and Therapeutic Targets

Overview

Journal Clin Rheumatol

Publisher Springer

Specialty Rheumatology

Date 2024 Aug 10

PMID 39126578

Authors

Qi Liu

Yuyang Liu

Hui Feng

Lin Zhao

Tao Wan

Affiliations

Soon will be listed here.

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by a significant health burden. There is an essential need for novel biomarkers and therapeutic targets to improve diagnosis and management. Mendelian randomization (MR) was applied to explore causal links between SLE and various biomarkers like immune cells, metabolites, and inflammatory cytokines using multiple databases. Initially, biomarkers significantly associated with SLE were identified. Bidirectional MR helped clarify these relationships, and a two-step mediation MR examined their effects on SLE risk. Intersection analysis was used to identify biomarkers with consistent effects across datasets. Four biomarkers were identified as having significant associations with SLE risk: 1-palmitoyl-2-arachidonoyl-GPI levels [odds ratio (OR), 1.379; 95% confidence interval (CI), 1.180 to 1.613; FDR, 0.046], IL-17A levels (OR, 2.197; 95% CI, 1.412 to 3.418; FDR, 0.044), N-acetyl-aspartyl-glutamate (NAAG) levels (OR, 0.882; 95% CI, 0.831 to 0.936; FDR, 0.030), and ribitol levels (OR, 0.743; 95% CI, 0.644 to 0.857; FDR, 0.012). Bidirectional MR showed an inverse effect of NAAG on IL-17A levels (OR, 0.978; 95% CI, 0.962 to 0.994; p = 0.006). Mediation analysis indicated that NAAG influenced SLE risk both directly (beta = - 0.108) and indirectly through IL-17A (beta = - 0.018), highlighting the potential mediating role of IL-17A. After expanding the significance criteria to p < 0.05, intersection analysis across multiple datasets revealed 29 biomarkers with consistent beta directions, including 19 potential risk factors (beta > 0) and 10 protective factors (beta < 0) for SLE. This research has revealed significant genetic associations with SLE and demonstrated that IL-17A mediates the relationship between NAAG levels and SLE risk, highlighting potential new targets for personalized therapeutic interventions. Key Points • This study employs MR to identify significant genetic associations between various biomarkers and SLE, providing novel insights into potential biomarkers and therapeutic targets. • Four key biomarkers were identified as significantly associated with SLE risk: 1-palmitoyl-2-arachidonoyl-GPI, IL-17A, N-acetyl-aspartyl-glutamate (NAAG), and ribitol. • The findings suggest that NAAG levels have a protective effect against SLE, partly mediated through IL-17A, indicating a complex interplay between these biomarkers in the pathogenesis of SLE. • Intersectional analysis across multiple datasets revealed 29 biomarkers with consistent effects on SLE risk, highlighting new directions for future research and potential personalized therapeutic strategies.

References

Kiriakidou M, Ching C . Systemic Lupus Erythematosus. Ann Intern Med. 2020; 172(11):ITC81-ITC96. DOI: 10.7326/AITC202006020. View

Tian J, Zhang D, Yao X, Huang Y, Lu Q . Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis. 2022; 82(3):351-356. PMC: 9933169. DOI: 10.1136/ard-2022-223035. View

Vinuesa C, Shen N, Ware T . Genetics of SLE: mechanistic insights from monogenic disease and disease-associated variants. Nat Rev Nephrol. 2023; 19(9):558-572. DOI: 10.1038/s41581-023-00732-x. View

Pan L, Lu M, Wang J, Xu M, Yang S . Immunological pathogenesis and treatment of systemic lupus erythematosus. World J Pediatr. 2019; 16(1):19-30. PMC: 7040062. DOI: 10.1007/s12519-019-00229-3. View

Gulati G, Brunner H . Environmental triggers in systemic lupus erythematosus. Semin Arthritis Rheum. 2017; 47(5):710-717. DOI: 10.1016/j.semarthrit.2017.10.001. View

Tsai C, Li K, Shen C, Lu C, Lee H, Wu T . Decipher the Immunopathological Mechanisms and Set Up Potential Therapeutic Strategies for Patients with Lupus Nephritis. Int J Mol Sci. 2023; 24(12). PMC: 10298725. DOI: 10.3390/ijms241210066. View

Niebel D, de Vos L, Fetter T, Bragelmann C, Wenzel J . Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions. Am J Clin Dermatol. 2023; 24(4):521-540. PMC: 10157137. DOI: 10.1007/s40257-023-00774-8. View

Li J, Liu M, Lei H . Characterization of anti-endothelial cell antibodies in the patients with systemic lupus erythematosus: a potential marker for disease activity. Clin Immunol Immunopathol. 1996; 79(3):211-6. DOI: 10.1006/clin.1996.0070. View

Reichlin M . Cell injury mediated by autoantibodies to intracellular antigens. Clin Immunol Immunopathol. 1995; 76(3 Pt 1):215-9. DOI: 10.1006/clin.1995.1118. View

10.

McClain M, Arbuckle M, Heinlen L, Dennis G, Roebuck J, Rubertone M . The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis Rheum. 2004; 50(4):1226-32. DOI: 10.1002/art.20120. View

11.

Accapezzato D, Caccavale R, Paroli M, Gioia C, Nguyen B, Spadea L . Advances in the Pathogenesis and Treatment of Systemic Lupus Erythematosus. Int J Mol Sci. 2023; 24(7). PMC: 10095030. DOI: 10.3390/ijms24076578. View

12.

Zen M, Salmaso L, Barbiellini Amidei C, Fedeli U, Bellio S, Iaccarino L . Mortality and causes of death in systemic lupus erythematosus over the last decade: Data from a large population-based study. Eur J Intern Med. 2023; 112:45-51. DOI: 10.1016/j.ejim.2023.02.004. View

13.

Ruiz-Irastorza G, Egurbide M, Pijoan J, Garmendia M, Villar I, Martinez-Berriotxoa A . Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus. 2006; 15(9):577-83. DOI: 10.1177/0961203306071872. View

14.

Siso A, Ramos-Casals M, Bove A, Brito-Zeron P, Soria N, Munoz S . Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus. 2008; 17(4):281-8. DOI: 10.1177/0961203307086503. View

15.

Alarcon G, McGwin G, Bertoli A, Fessler B, Calvo-Alen J, Bastian H . Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007; 66(9):1168-72. PMC: 1955128. DOI: 10.1136/ard.2006.068676. View

16.

Katarzyna P, Wiktor S, Ewa D, Piotr L . Current treatment of systemic lupus erythematosus: a clinician's perspective. Rheumatol Int. 2023; 43(8):1395-1407. PMC: 10261264. DOI: 10.1007/s00296-023-05306-5. View

17.

Trager J, Ward M . Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol. 2001; 13(5):345-51. DOI: 10.1097/00002281-200109000-00002. View

18.

Cervera R, Khamashta M, Font J, Sebastiani G, Gil A, Lavilla P . Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003; 82(5):299-308. DOI: 10.1097/01.md.0000091181.93122.55. View

19.

Kasitanon N, Magder L, Petri M . Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore). 2006; 85(3):147-156. DOI: 10.1097/01.md.0000224709.70133.f7. View

20.

Urowitz M, Gladman D, Tom B, Ibanez D, Farewell V . Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol. 2008; 35(11):2152-8. DOI: 10.3899/jrheum.080214. View